SCHEMBL4922740

SCHEMBL4922740

CC1(C)CC(=O)c2c(S(C)(=O)=O)sc(C(=O)c3cc(-c4ccc(Cl)cc4)no3)c2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.41
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 3/20 0.35
ALPL P05186 1/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 2/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
MEN1 O00255 2/20 0.34
SRC P12931 1/20 0.33
PLAU P00749 1/20 0.33
WRN Q14191 1/20 0.32
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927639 0.82 LRRK2 (0.44) LRRK2SMN1; SMN2MAPTALDH1A1PKM
SCHEMBL4928068 0.81 LRRK2 (0.47) LRRK2SMN1; SMN2MAPTALDH1A1PKM
SCHEMBL4924642 0.78 ALDH1A1 (0.52) LRRK2RAB9ASMN1; SMN2MAPTCYP1A2
SCHEMBL4919003 0.73 LRRK2 (0.46) LRRK2RAB9ASMN1; SMN2MAPTCYP1A2
SCHEMBL4928631 0.73 LRRK2 (0.46) LRRK2RAB9AALDH1A1PKMLMNA
SCHEMBL14007313 0.73 LRRK2 (0.43) LRRK2SMN1; SMN2MAPTALDH1A1PKM
SCHEMBL4923725 0.73 ALDH1A1 (0.51) LRRK2SMN1; SMN2ALDH1A1PKMLMNA
SCHEMBL4927681 0.72 LRRK2 (0.45) LRRK2ALDH1A1PKMLMNAPTGS1
SCHEMBL4927720 0.71 LRRK2 (0.48) LRRK2MAPTALDH1A1PKMLMNA
SCHEMBL4928078 0.71 ALDH1A1 (0.49) LRRK2RAB9AMAPTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
EP-1765814-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006003096-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists GLP1R, GIPR, GCGR LRRK2 327/4885NPC1 1074/4885RAB9A 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.